search
Back to results

Plasma Exchange Combination of Immunosuppressive Regimens for Auto-immune Hepatitis

Primary Purpose

Hepatitis, Autoimmune

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Plasma exchange combination of immunosuppressive regimens
Sponsored by
Xiaoli Fan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatitis, Autoimmune

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosed with auto-immune hepatitis based on liver biopsy results, with the indications of immunosuppressive therapy;
  • High levels of total bilirubin (TB) (≥10 X ULN);
  • High levels of immunoglobulin G(IgG) (≥1.5 X ULN);
  • Agreed to participate in the trial, and assigned informed consent;

Exclusion Criteria:

  • The presence of hepatitis A, B, C, D, or E virus infection;

    • Patients with presence of liver cirrhosis or portal hypertension;
    • Primary sclerosing cholangitis, non-alcoholic steatohepatitis, drug induced liver disease or Wilson disease confirmed by liver biopsy;
    • Pregnant and breeding women;
    • Patients with severe anemia (hemoglobin < 8 g/dL), leukopenia (WBC < 2500/mm3), or thrombocytopenia (platelet count < 50,000/mm3);
    • Severe disorders of other vital organs, such as severe heart failure, cancer;
    • Parenteral administration of blood or blood products within 6 months before screening;
    • Recent treatment with drugs having known liver toxicity;
    • Taken part in other clinic trials within 6 months before screening.

Sites / Locations

  • West China HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Plasma exchange combination of immunosuppressive regimens

Arm Description

Plasma exchange(once) ,with the following standard immunosuppressive regimens for the remission of auto-immune hepatitis

Outcomes

Primary Outcome Measures

Percent of patients that achieve biochemical remission of AIH

Secondary Outcome Measures

Alanine transaminase (ALT)
Aspartate transaminase(AST)
Globin(GLB)
Immunoglobulin G(IgG)
Total bilirubin(TB)
Direct bilirubin(DB)

Full Information

First Posted
August 17, 2016
Last Updated
November 7, 2020
Sponsor
Xiaoli Fan
search

1. Study Identification

Unique Protocol Identification Number
NCT02874586
Brief Title
Plasma Exchange Combination of Immunosuppressive Regimens for Auto-immune Hepatitis
Official Title
Plasma Exchange Combination of Immunosuppressive Regimens for the Remission of Auto-immune Hepatitis
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Unknown status
Study Start Date
December 2016 (undefined)
Primary Completion Date
April 2021 (Anticipated)
Study Completion Date
September 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Xiaoli Fan

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
An open-label,pilot study to evaluate the efficacy and safety of plasma exchange combination of immunosuppressive regimens, for the remission of autoimmune hepatitis (AIH).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatitis, Autoimmune

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Plasma exchange combination of immunosuppressive regimens
Arm Type
Experimental
Arm Description
Plasma exchange(once) ,with the following standard immunosuppressive regimens for the remission of auto-immune hepatitis
Intervention Type
Other
Intervention Name(s)
Plasma exchange combination of immunosuppressive regimens
Primary Outcome Measure Information:
Title
Percent of patients that achieve biochemical remission of AIH
Time Frame
Month 6 after the treatment initiated
Secondary Outcome Measure Information:
Title
Alanine transaminase (ALT)
Time Frame
Day 1, and Week 1, 2, 4, 12, 24
Title
Aspartate transaminase(AST)
Time Frame
Day 1, and Week 1, 2, 4, 12, 24
Title
Globin(GLB)
Time Frame
Day 1, and Week 1, 2, 4, 12, 24
Title
Immunoglobulin G(IgG)
Time Frame
Day 1, and Week 1, 2, 4, 12, 24
Title
Total bilirubin(TB)
Time Frame
Day 1, and Week 1, 2, 4, 12, 24
Title
Direct bilirubin(DB)
Time Frame
Day 1, and Week 1, 2, 4, 12, 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosed with auto-immune hepatitis based on liver biopsy results, with the indications of immunosuppressive therapy; High levels of total bilirubin (TB) (≥10 X ULN); High levels of immunoglobulin G(IgG) (≥1.5 X ULN); Agreed to participate in the trial, and assigned informed consent; Exclusion Criteria: The presence of hepatitis A, B, C, D, or E virus infection; Patients with presence of liver cirrhosis or portal hypertension; Primary sclerosing cholangitis, non-alcoholic steatohepatitis, drug induced liver disease or Wilson disease confirmed by liver biopsy; Pregnant and breeding women; Patients with severe anemia (hemoglobin < 8 g/dL), leukopenia (WBC < 2500/mm3), or thrombocytopenia (platelet count < 50,000/mm3); Severe disorders of other vital organs, such as severe heart failure, cancer; Parenteral administration of blood or blood products within 6 months before screening; Recent treatment with drugs having known liver toxicity; Taken part in other clinic trials within 6 months before screening.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xiaoli Fan, MM
Phone
+862885422311
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Li Yang, MD
Organizational Affiliation
West China Hospital,Chengdu, Sichuan, China
Official's Role
Study Chair
Facility Information:
Facility Name
West China Hospital
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610041
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Li Yang, MD
Phone
+8618980601276
Email
yangli_hx@scu.edu.cn

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Plasma Exchange Combination of Immunosuppressive Regimens for Auto-immune Hepatitis

We'll reach out to this number within 24 hrs